Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Most Down Articles

    Published in last 1 year | In last 2 years| In last 3 years| All| Most Downloaded in Recent Month | Most Downloaded in Recent Year|

    In last 2 years
    Please wait a minute...
    For Selected: Toggle Thumbnails
    Progress in clinical application of topical anesthesia
    TAO Yijia, YANG Chun, LIU Cunming
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (5): 594-600.   DOI: 10.12092/j.issn.1009-2501.2023.05.015
    Abstract348)      PDF (614KB)(2834)       Save
    Topical anesthesia are being widely used in clinical diagnostic or therapeutic fields such as ophthalmology, ENT, dermatology, urology. It is defined as superficial loss of sensation in mucous membranes or skin, produced by direct application of penetrating local anesthetics. Topical anesthesia has the advantages of simple performance, high safety, quick recovery, which can effectively improve patient's satisfaction. In recent years, more and more attention has been paid to the concept of comfortable diagnosis and treatment. The new drugs and application methods of topical anesthesia are emerging constantly, special attention must be paid to their pharmacological characteristics and possible adverse reactions when using them. This article reviews the research progress of topical anesthesia in clinical application in order to provide reference for clinical practice.
    Related Articles | Metrics
    Progress on the pathological mechanism and treatment of frostbite 
    ZHANG Li, LIN Xingyao, SHANG Yun, WANG Qiang
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (3): 347-354.   DOI: 10.12092/j.issn.1009-2501.2023.03.014
    Abstract400)      PDF (808KB)(1436)       Save
    Frostbite is a tissue injury that occurs when the body is exposed to extreme cold. Its path-ological mechanism is complex and has not been ful-ly elucidated. In high cold and high altitude areas, outdoor sports people have a high risk of injury, and severe frostbite has high disability and mortality. Ex-ploring the pathological mechanism of frostbite is helpful to determine the treatment methods and timing. At present, the clinical treatment of frostbite is mainly symptomatic treatment, such as drug treatment and surgical treatment, but the curative effect can not meet the clinical needs. Therefore, it is of great significance to seek more efficient drugs or treatment methods. This article reviews the rele-vant research progress in pathophysiological mecha-nism, clinical treatment, cellular and molecular path-ways of frostbite in recent years, in order to provide new ideas for future research and clinical treatment. 
    Related Articles | Metrics
    Research progress in the treatment of early Alzheimer's disease with lecanemab
    JIN Panpan, LIU Yang, QIU Bo, WU Huizhen
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (2): 207-214.   DOI: 10.12092/j.issn.1009-2501.2024.02.011
    Abstract512)      PDF (672KB)(1139)       Save
    Lecanemab is a new drug used to treat early Alzheimer's disease (AD) with mild cognitive impairment or mild dementia. It is a human anti-Aβ fibril monoclonal IgG1 antibody, which is injected intravenously into the patient, through the blood-brain barrier into the brain, clearing amyloid plaque, thereby slowing the rate of cognitive decline in patients and delaying disease progression. This article reviews the pharmacological studies, clinical studies, safety and limitations of lecanemab, in order to help clinical understand the current research status and existing achievements of this drug.
    Related Articles | Metrics
    Progress in clinical research on remazolam
    XIN Yuqi, CAO Ya, WANG Yulong
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (10): 1195-1200.   DOI: 10.12092/j.issn.1009-2501.2023.10.014
    Abstract405)      PDF (624KB)(857)       Save
    Benzodiazepines are among the most commonly used drugs in the field of anesthesia. Remazolam is a newly developed ultra-short-acting benzodiazepine, which has the characteristics of rapid onset, rapid recovery, high safety, and less side effects such as hypotension and respiratory depression. The aim of this review is to summarize the progress of pharmacokinetics, clinical pharmacology mechanism of action and clinical application of remazolam.
    Related Articles | Metrics
    Research progress of the classical TCM formula Huaihua powder 
    CHEN Cheng, DENG Yu, GONG Youlan, ZHANG Zhenming, DUAN Wulei, QING Jun, ZHANG Bo
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (6): 697-704.   DOI: 10.12092/j.issn.1009-2501.2023.06.013
    Abstract373)      PDF (734KB)(789)       Save
    Huaihua powder, a classical TCM formula, was initially recorded in Pu Ji Ben Shi Fang by the prestigious physician Xu Shuwei. It is a classical prescription for treating "chang-feng-zang-du"(chang-feng-xia-xue). Modern research shows that the main components of Huaihua powder are flavonoids, volatile oil, saponins and so on, which have anti-inflammatory, antioxidant, hemostatic, antibacterial, anti-tumor and other pharmacological effects.The clinical application is mostly used for the treatment of ulcerative colitis, radioactive enteritis, hemorrhoid postoperative bleeding and other skin diseases. Its modern clinical application is slightly better than the ancient clinical application. This paper summarized and summarized the chemical composition and analysis method, process research and quality control, modern pharmacology and clinical application, and discussed the material basis and research direction of its efficacy. Based on the research results, combined with the modern pharmacology and clinical application of Huaihua powder, it is recommended to develop the entire pharmacological active ingredients of this classic formula, as well as the main effective ingredients, anti-inflammatory targets, and mechanism of action for the treatment of radiation induced enteritis, allergic purpura, and other skin diseases.
    Related Articles | Metrics
    Research progress of lactate dehydrogenase A in digestive system tumors and related drugs
    WANG Siyu, LI Jiawei, LI Chenghao, LI Ling, GUO Qingyang, QIU Lu, ZHOU Shiqin, LIU Yongqi
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (4): 445-454.   DOI: 10.12092/j.issn.1009-2501.2023.04.012
    Abstract537)      PDF (1441KB)(765)       Save
    Malignant tumors of digestive system are highly prevalent malignant tumors that seriously threaten human health around the world. At present, the curative efficacy and prognosis of traditional treatment methods cannot reach the expectation, so it is urgent to find new targets for cancer treatment and realize targeted therapy for tumors. Abnormal energy metabolism in tumor  cells is regarded as a hallmark of cancer, and malignant tumor cells absorb glucose through aerobic glycolysis pathway, and obtain a small amount of energy and produce lactate under the catalysis of a series of enzymes. Lactate dehydrogenase A (Lactate dehydrogenase A, LDHA), as a key enzyme in the aerobic glycolysis pathway of tumor cells, plays an important role in the metabolic changes of tumor cells. Studies have demonstrated that LDHA has high expression characteristics in a variety of tumor cells,and its high expression in clinic is often related to the poor prognosis and high metastasis rate of tumors, which is expected to be a new target for cancer therapy. This article reviews the role of LDHA in the development of digestive system tu- mors and the research progress of related drugs.
    Related Articles | Metrics
    Analysis and verification of the effect of Yi Qi Yang Yin decoction on rheumatoid arthritis
    GUAN Rui, YAO Jiashu, ZHAO Yeyu, ZHENG Jiannan, QI Qing, YU Jing, GAO Mingli
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (1): 26-36.   DOI: 10.12092/j.issn.1009-2501.2024.01.003
    Abstract147)      PDF (5757KB)(737)       Save
    AIM: Yi Qi Yang Yin Decoction (YQYY) has been used to treat patients with rheumatoid arthritis (RA) and achieved good results in clinical applications, but the mechanism still needs to be explored. The purpose was to investigate the mechanism of YQYY in rats with collagen-induced arthritis. METHODS: The possible treatment target and signaling pathway were predicted by bioinformatics and network pharmacology analysis. Elisa,quantitative real-time polymerase chain reaction, and Western Blot were used to verify the mechanism of YQYY in treating RA. RESULTS: FABP4, MMP9 and PTGS2 were the most common predicational therapeutic targets. The results of pathology and CT showed that YQYY could improve ankle swelling, synovitis and bone erosion in CIA rats. Compared with the model group, YQYY or YQYY+MTX can significantly reduce the secretion of CRP, TNF-α, IL-1β and FABP4 in serum of CIA rats (P<0.05 or P<0.01), meanwhile, reduce the mRNA of FABP4, IKKα and p65 in synovial tissue (P<0.01), PPARγ was increased (P<0.01). YQYY could significantly reduce the expression of FABP4, IKKα and pp65 proteins in synovium, and suppress the activate of NF-κB signaling pathway. CONCLUSION: FABP4, MMP9 and PTGS2 may be the targets of YQYY decoction for RA treatment. YQYY can relieve joint symptoms in CIA rats, and regulate inflammation by inhibiting FABP4/PPARγ/NF-κB signaling pathway, playing a role in the treatment of RA. The effect of YQYY combined with MTX was more prominent. This provided experimental evidence for the efficacy of YQYY decoction in clinical practice.
    Related Articles | Metrics
    Research progress on mechanisms and therapeutic drugs of peroxisome proliferator-activated receptor in treatment of cholestatic liver disease
    WANG Anjing, WANG Yaya, LIANG Xuan, YAN Yajie, SU Jing, LI Caidong
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (7): 796-808.   DOI: 10.12092/j.issn.1009-2501.2023.07.011
    Abstract312)      PDF (851KB)(733)       Save
    Cholestatic liver disease is a common disease that causes bile flow dysfunction due to various reasons. The etiology of cholestatic liver disease is complexed, and therapeutic drugs are extremely limited. To date, ursodeoxycholic acid is the only FDA-approved drug for treating primary biliary cirrhosis, whereas its efficacy is limited to early stage of the disease, therefore novel drugs are urgently needed. Nuclear receptors become therapeutic hotspot target in cholestasis since these receptors play a key role in regulating bile acid homeostasis. Peroxisome proliferator-activated receptor (PPAR) is an important nuclear receptor involved in regulating multiple mechanisms of cholestasis in vivo. It can improve intrahepatic cholestasis by inhibiting bile acid synthesis, reducing bile acid toxicity, affecting the expression of bile acid metabolic enzymes and transporters, and can play an anti-inflammatory, anti-oxidation and anti-fibrosis role. A number of studies have shown that PPAR agonists represented by fibrates alone or in combination can improve liver function indexes, inflammatory factors and fibrosis markers in patients with cholestasis. This review analyzes and summarizes the lastest advances in the molecular mechanism of PPAR as a therapeutic target for cholestasis and drug treatment in development or have been used in clinical.
    Related Articles | Metrics
    Progress in the clinical application of the biased μ-opioid agonist oliceridine
    ZHU Changmao, XIE Li, WU Zifeng, WANG Sen, ZHANG Qi, XU Xiangqing, YANG Chun
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (9): 1057-1061.   DOI: 10.12092/j.issn.1009-2501.2024.09.012
    Abstract277)      PDF (596KB)(703)       Save
    Opioid receptors μOR, δOR, κOR and NOPR are all G protein-coupled receptors (GPCRs), which mainly function through G protein and β-arrestin. Recent studies have found that G protein mediates analgesia, while β-arrestin reduces analgesia and is related to the side effects of opioids. Oliceridine is the first biased μOR agonist approved for commerce. It mainly exerts analgesic effect by activating G protein. It has rapid onset of action and reliable analgesic effect. Due to its low activity on β-arrestin, the incidence of side effects is low, comparing to the classic opioid morphine. Oliceridine can be safely used in patients with liver or kidney insufficiency and its metabolite is inactive. This article summarizes the current progress of pharmacological research and clinical application of oliceridine, aiming to provide reference for the clinical practice of oliceridine.
    Related Articles | Metrics
    Research progress of uterine endometrial epithelial cell organoids in the field of reproduction
    CAO Zhiwen, YAN Guijun
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (5): 576-582.   DOI: 10.12092/j.issn.1009-2501.2024.05.013
    Abstract368)      PDF (829KB)(697)       Save
    In recent years, significant progress has been made in the study of endometrial epithelial organoids in the field of reproduction. Traditional two-dimensional cell culture models and animal experiments fail to accurately replicate the three-dimensional structure and physiological functions of the endometrium, limiting the in-depth exploration of its normal physiological mechanisms and related disease mechanisms. Emerging organoid technologies have provided new avenues for research. These organoids, formed by self-organization of stem cells or progenitor cells in a three-dimensional culture system, faithfully recapitulate the characteristics of endometrial glands in situ. Not only can these organoid models mimic the changes in the endometrium at different stages of the menstrual cycle, but they can also simulate the interaction between the fertilized embryo and the endometrium. Moreover, organoid systems have become essential tools for fundamental research in the field of reproduction and for disease research, including studies related to reproductive biology, drug screening and development, disease mechanism exploration, drug action mechanisms, drug combination therapies, and targeted therapies. These studies have provided novel insights and methods for a deeper understanding of the biological properties of the endometrium, its disease mechanisms, and the development of therapeutic strategies for related disorders.
    Related Articles | Metrics
    PDE4 inhibitors serve as therapeutic targets for pulmonary fibrosis 
    LIU Nanyu, YUE Hongmei, SONG Peipei, WEI Jifang, WEI Yaqian, XIE Yingying, WANG Jiaqi
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (3): 355-360.   DOI: 10.12092/j.issn.1009-2501.2023.03.015
    Abstract544)      PDF (665KB)(677)       Save
    Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal chronic interstitial lung disease characterized by a progressive decline in lung function, and current treatment options are limited. cAMP is one of the most important second messengers and plays a key role in relaxing airway smooth muscle cells and reducing inflammation. Phosphodiesterase (PDE) is a superfamily of enzymes, and PDE4 enzymes dominate 11 PDE super-family enzymes, available in four isoforms-PDE4A, PDE4B, PDE4C and PDE4D, which selectively decompose cAMP, while PDE4 inhibitors increase cAMP levels by preventing cAMP from breaking down, thereby exerting anti-inflammatory, anti-remodeling effects and providing an attractive drug target for the treatment of IPF. This review summarizes knowledge about the association of pulmonary fibrosis with PKE4, as well as emerging preclin-ical studies and clinical trials regarding PDE4 inhibitors.
    Related Articles | Metrics
    Research progress on immunotherapy for triple-negative breast cancer
    HE Lihua, ZHU Xiuzhi, JIANG Yizhou
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (8): 842-853.   DOI: 10.12092/j.issn.1009-2501.2023.08.001
    Abstract777)      PDF (754KB)(647)       Save
    Triple-negative breast cancer (TNBC) is a subtype of breast cancer characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). It is highly aggressive, easy to relapse, and chemotherapy remains its mainstay treatment due to the lack of therapeutic targets. In recent years, many advances have been made in the development of immunotherapy for TNBC. This review summarizes the primary modalities of immunotherapy for TNBC, including immune checkpoint inhibitors, adoptive immune cell therapy, tumor vaccines and oncolytic virus. We present the latest research progress on each treatment from the perspective of clinical study and fundamental research, while introducing the potential predictive biomarkers and resistance mechanisms of immunotherapy for TNBC.
    Related Articles | Metrics
    Research progress in plasma concentration monitoring of rivaroxaban
    YU Qiaoling, ZHAI Weiwei, LIU Ping, QIU Bo, WU Huizhen
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (7): 809-817.   DOI: 10.12092/j.issn.1009-2501.2023.07.012
    Abstract375)      PDF (654KB)(646)       Save
    Rivaroxaban, a novel oral anticoagulant drug, is widely prescribed in clinical practice. Rivaroxaban offers predictable pharmacokinetic and pharmacodynamic properties, a lowprobability of drug-drug and food-drug interactions. Compared with warfarin, rivaroxaban does not require continuous therapeutic monitoring and can be administered in fixed doses.However,in certain emergency clinical situations, such as bleeding, acute stroke, acute kidney injury, prior to urgent surgery and in the suspected accumulation of durg, plasma concentration monitoring of rivaroxaban is necessary and important for patients. Existing studies proved that there were significant individual variability and wide range in the plasma rivaroxaban concentration, which increased the risk of clinical use. Therefore, Data in the degree of rivaroxaban concentration may provide recommendations for the clinical application to promote medication safety and individuality in the future. This article collected the latest literatures and case reports related to research progress of rivaroxaban plasma concentration monitoring, and Summarized influencing factors, monitoring methods, so as to provide a basis for further study on rational use of rivaroxaban in clinical.
    Related Articles | Metrics
    Pharmacokinetic interaction study between sorafenib and dapagliflozin in rats
    HE Xueru, LI Ying, MA Yinling, FU Yuhao, XUN Xuejiao, DONG Zhanjun
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (5): 498-507.   DOI: 10.12092/j.issn.1009-2501.2023.05.003
    Abstract241)      PDF (1822KB)(616)       Save
    AIM: To explore the pharmacokinetic interactions between sorafenib and dapagliflozin in rats and to provide some theoretical basis for the rational clinical use of the two drugs. METHODS: An ultra-performance liquid chromatography-tandem mass spectrometry (UPLC/MS/MS) method was developed for the simultaneous determination of sorafenib and dapagliflozin. Male SD rats were randomly divided into 5 groups (6 rats in each group), including 100 mg/kg sorafenib group, 0.5 mg/kg dapagliflozin group, 1 mg/kg dapagliflozin group, and 100 mg/kg sorafenib combined with 0.5 mg/kg dapagliflozin group and 100 mg/kg sorafenib combined with 1 mg/kg dapagliflozin group, for sorafenib and dapagliflozin drug interaction study. All samples were analyzed using a validated UPLC/MS/MS method, and the main pharmacokinetic parameters were calculated by compartment model. RESULTS: 1 mg/kg dapagliflozin increased the Cmax, AUC0-t and AUC0-∞ of sorafenib by 52.5%, 38.1% and 37.7%, respectively, and 0.5 mg/kg dapagliflozin increased the AUC0-t and AUC0-∞ of sorafenib by 36.3% and 36.3%. CONCLUSION: Pharmacokinetic interactions may exist between sorafenib and dapagliflozin, active surveillance for treatment and toxicity should be required when the two drugs combined together in clinical practice.
    Related Articles | Metrics
    Research progress in population pharmacokinetics of rituximab
    LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (4): 468-474.   DOI: 10.12092/j.issn.1009-2501.2023.04.015
    Abstract513)      PDF (638KB)(613)       Save
    Rituximab, a chimeric human-mouse monoclonal antibody, has been used as a first-line treatment for CD20+ B-cell non-Hodgkin lymphoma in combination with chemotherapy. It is also used for autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus and immunemediated nephropathy. The clinical therapeutic effect of rituximab is significant. However, individual pharmacokinetics vary greatly, which bring some uncertainties to the efficacy and safety of clinical application, individualized treatment is needed to improve the rationality of its medication. Currently, studies on the optimization of rituximab administration regimen using population pharmacokinetics have been reported. Our paper reviewed the research progress in population pharmacokinetics of rituximab, aiming to provide reference to formulate an individualized dosing scheme of rituximab and realize precise administration for domestic patients.
    Related Articles | Metrics
    Progress on anti-tumor mechanisms of Ganoderma lucidum active ingredients
    LV Yujiao, ZHOU Shuting, WANG Lina, SHEN Mingmei, LIU Yongchao
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (8): 947-954.   DOI: 10.12092/j.issn.1009-2501.2024.08.012
    Abstract257)      PDF (712KB)(613)       Save
    Malignant tumors are one of the main causes of death from chronic diseases in China, and their incidence and mortality rates show an increasing trend year by year. Advanced non-surgical treatment of malignant tumors is an important means of improving patients' prognosis and enhancing their quality of life. The traditional Chinese medicine Ganoderma lucidum has anti-tumor effects and plays a role in the treatment of many malignant tumors. In this paper, a systematic review of the effects of Ganoderma lucidum active ingredients on tumors has been conducted at home and abroad in the past five years to explore the anti-tumor mechanism of Ganoderma lucidum active ingredients and to lay a theoretical foundation for the application of Ganoderma lucidum active ingredients in clinical practice.
    Related Articles | Metrics
    Research progress on CXC chemokines and their receptors and pulmonary fibrosis
    CHEN Feng, LI Long, WANG Jie, LIU Shengfei
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (5): 583-589.   DOI: 10.12092/j.issn.1009-2501.2024.05.014
    Abstract185)      PDF (665KB)(597)       Save
    Pulmonary fibrosis (PF) is a common, persistent, irreversible, fatal chronic lung disease with a median survival of 2-4 years after diagnosis. It is characterized by excessive extracellular matrix deposition and scarring in the lungs, leading to functional failure, severe respiratory problems and even death. Numerous studies have shown that CXC chemokines and their receptors play important roles in PF and other desmoplastic disorders. Several studies have shown that chemokines may become new targets for the treatment of many diseases. Here, we review the role of key CXC chemokines and their receptors in PF to provide a reference for the treatment of PF.
    Related Articles | Metrics
    Application of quantitative pharmacology in vaccine research and de-velopment: overview and prospect 
    MA Guangli, ZHANG Jing
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (3): 315-322.   DOI: 10.12092/j.issn.1009-2501.2023.03.010
    Abstract344)      PDF (1748KB)(595)       Save
    This article introduces the mechanism including antigen presentation, adjuvant, lymphatic system and the characteristics of vaccine, and then summarizes the key applications of core pharmaco-metrics approaches including QSP, PK/PD, dose re-sponse analysis, MBMA, in dose-response, preclini-cal and clinical translation, and correlation be-tween biomarkers and efficacy of vaccines. It is ex-pected that the successful application of model in-formed drug development can promote model in-formed vaccine development so that pharmaco-metrics makes its due contributions to the develop-ment of safer, more effective and more controlla-ble vaccine products.
    Related Articles | Metrics
    Mechanism of tyrosine kinase 2 inhibitors in treatment of plaque psoriasis and their progress in clinical trials 
    SHEN Jiaqing, LIU Yi
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (3): 323-330.   DOI: 10.12092/j.issn.1009-2501.2023.03.011
    Abstract292)      PDF (1286KB)(575)       Save
    As a chronic, immune-mediated in-flammatory disease, plaque psoriasis has a great burden of disease and influences on patient's physi-cal and mental health. In the past decade, plaque psoriasis treatment with biological agents achieved breakthrough development, while oral drugs with promising efficacy and safety are yet to be met. By cell signal transduction, the Janus kinase-signal transducer and activator of transcription pathway plays an important role in numerous immune-relat-ed diseases. Tyrosine kinase 2 (TYK2), a member of the JAK family, can impact on plaque psoriasis by regulating signaling and functional responses down-stream of IL-12, IL-23, IFN. Deucravacitinib, a highly selective TYK2 inhibitor, has finished its phase 3 clinical trials and shown its efficacy and safety in treatment of plaque psoriasis. Several kinds of TYK2 inhibitors are under research and develop-ment at the moment. In this review, we demon-strate roles of JAK-STAT pathway and TYK2 in plaque psoriasis as well as updates on ongoing and recently completed trials of TYK2 inhibitors. 
    Related Articles | Metrics
    Mechanism of action and research progress of vaccine adjuvants
    ZHANG Li, LU Chang, AN Minghui, WANG Mengmeng, ZONG Xiaoyu, YU Lin, RAN Zhuo-ling, SONG Jing, LI Huijie, GONG Jian
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (7): 785-791.   DOI: 10.12092/j.issn.1009-2501.2024.07.008
    Abstract316)      PDF (831KB)(563)       Save
    Vaccines are among the most effective measures for preventing infectious diseases and play a crucial role in controlling the spread of these diseases. Adjuvants, serving as auxiliary components in vaccines, are indispensable in the vaccine development process. Ideal adjuvants not only enhance the immune response, enabling the body to achieve optimal protective immunity but also play important roles in reducing the dosage of immunogens and lowering vaccine production costs. To meet the demands of novel vaccines, many new types of adjuvants have been developed. However, there is still a lack of adjuvants that are safe, effective, easy to prepare, highly pure, and suitable for a variety of vaccines in clinical settings. This article categorizes adjuvants and summarizes their mechanisms of action and characteristics, focusing on traditional aluminum salt adjuvants and more modern lipid-based and nucleic acid-based adjuvants. The summary is based on a computer search of databases including PubMed, Embase, The Cochrane Library, CNKI (China National Knowledge Infrastructure), VIP Database, and Wanfang Database, using English search keywords such as Adjuvants, Vaccine, Vaccine Adjuvant, aluminum salts, MF59, AS03, Toll-like receptor agonist, etc., and corresponding Chinese search terms. The aim is to provide references for the development and application of adjuvants.
    Related Articles | Metrics
    Research progress of JAK/STAT signaling pathway in the intervention of diabetic microvascular complications
    LI Tao, YANG Lixia, GAO Bo, LI Qin, SONG Shuang
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (12): 1415-1421.   DOI: 10.12092/j.issn.1009-2501.2023.12.012
    Abstract188)      PDF (685KB)(552)       Save
    Diabetic microvascular complications are the main reason for the high mortality of diabetic patients. There is still a great shortage of existing therapeutic drugs, so there is an urgent need for more effective new drugs. Janus kinase/signal transducer and activator of transcription (JAK/STAT) is involved in the progression of diabetic microvascular complications, which can be improved by regulating this pathway. Therefore, this article reviews the progress of JAK/STAT in diabetic microvascular complications (diabetic kidney disease, diabetic retinopathy, diabetic peripheral neuropathy), and summarizes the potential drugs that intervene JAK/stat to improve diabetic microvascular complications in recent years from three aspects of therapeutic drugs, preclinical drugs, and traditional Chinese medicine, in order to provide ideas for drug development and treatment of diabetic microvascular complications.
    Related Articles | Metrics
    Research progress on pathogenesis and potential therapeutic target of sarcopenia obesity 
    GUO Yixun, GUAN Xiaoyin, WANG Bo, WEI Yingda, ZHANG Yan, LIN Jianhua
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (3): 341-346.   DOI: 10.12092/j.issn.1009-2501.2023.03.013
    Abstract343)      PDF (631KB)(548)       Save
    Sarcopenia obesity (SO), a specific dis-ease with co-occurrence of obesity and sarcopenia, is shown clinically as abnormal accumulation of fat, decreased mass and strength of muscle, and in-creased risk of incidence and mortality of other chronic diseases. Currently, there exist various defi-nitions and diagnoses about SO in the various re-gions of the world. Its prevalence in populations el-evates in an age-dependent manner. This article summarized the possible pathogenesis of SO from the view of chronic inflammation, oxidative stress, insulin resistance, and Hippo pathway, subsequent-ly listed and analyzed potential pharmacological targets (fibroblast growth factor, CD44, adiponec-tin, etc) involved in treating SO, in order to provide new ideas for clinical diagnosis, treatment of SO pa-tients and research and development of innovative drugs.
    Related Articles | Metrics
    Research progress on drug treatment and drug resistance mechanism of gastrointestinal stromal tumors
    ZHAO Quanming, YANG Mandou, HU Yibo, SU Youtong, PU Li, ZHANG Yu, LI Wenliang
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (1): 82-89.   DOI: 10.12092/j.issn.1009-2501.2024.01.009
    Abstract316)      PDF (835KB)(537)       Save
    Gastrointestinal stromal tumors (GIST) are the most common mesenchymal-derived tumors of the gastrointestinal tract. Tyrosine kinase inhibitors (TKIs) are the cornerstone of GIST therapy, but mutations in resistance genes pose many problems for treatment, especially the heterogeneity of KIT resistance mutations. In recent years, with the release of a number of GIST related drug research and experimental results, the great potential of targeted therapy, immunotherapy and combination therapy to treat GIST in different directions has been revealed, providing more therapeutic directions for GIST. This article will review the experimental research and future direction in recent years.
    Related Articles | Metrics
    Platelet-endothelial aggregation receptor 1 and its mediated signalling pathway Advances in the study of the role of platelets and endothelial cells
    LI Ruoning, GUO Zhanli, WANG Yuan, SUN Jianjun
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (4): 438-444.   DOI: 10.12092/j.issn.1009-2501.2023.04.011
    Abstract401)      PDF (1248KB)(525)       Save
    Platelet-aggregation  receptor 1 (PEAR1) is a transmembrane receptor identified in 2005 and expressed mainly on platelets and endothelial cells. PEAR1 is a receptor protein that contacts platelets with each other and plays an important role in platelet activation and aggregation. Endothelial cells play an important role in maintaining vascular tone and vascular repair, and PEAR1 regulates the process of tumourigenesis and development by affecting their proliferation and associated neovascularisation. In recent years, PEAR1 has gradually been recognized as a potential target for anti-thrombotic drugs. This review focuses on elucidating the mechanisms of platelet endothelial aggregation receptor 1 and related signaling pathways in platelets and endothelial cells, and provides new ideas for the study of drug therapy for tumour-associated thrombosis.
    Related Articles | Metrics
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (3): 357-.  
    Abstract112)      PDF (227KB)(519)       Save
    Related Articles | Metrics
    Progress and prospect of inhaled biological agents in asthma
    LI Guanghui, HUANG Jing, ZHU Min, ZHAO Rui, WAN Yakun, CHEN Zhihong
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (4): 406-414.   DOI: 10.12092/j.issn.1009-2501.2024.04.007
    Abstract390)      PDF (904KB)(508)       Save
    More than 300 million people worldwide suffer from asthma, and the incidence is increasing year by year. As one of the most common chronic diseases, asthma is an immune-mediated inflammatory disease with complex triggering mechanisms and strong heterogeneity. With the in-depth study of physiological and pathological mechanisms, therapeutic small molecule and hormone drugs have been introduced to control and treat most patients, but about 5%-10% of patients still suffer from various subtypes of difficult to control and treat asthma, that is, severe asthma. In the past decade, with the rapid development of biopharmaceutical research, protein and antibody have become the key drugs for the treatment of severe asthma with high efficacy, high specificity and high safety. However, biological drugs are usually administered by injection, they cannot be noninvasive and directly delivered into the lung to quickly absorb and take effect. Therefore, there is an urgent need for the introduction of inhaled biologics with quick effectiveness, convenience, economy and safety in clinical. The review summarizes the existing small molecule, hormone and biological therapy drugs, and summarizes the development of inhalable biological agents of asthma, and analyzes the future prospects of the inhalable biological drugs, which is designed to deepen the perception of the direction of the inhalable biological drugs research, and update the information of the field, in order to provide reference for the development of more inhalable biologics.
    Related Articles | Metrics
    Advances of VEGF signalling pathway in hepatocellular carcinomar invasion and metastasis and therapy
    LAN Xueling, HUANG Yanni, ZHU Minmin, MA Ping, DONG Min
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (6): 707-714.   DOI: 10.12092/j.issn.1009-2501.2024.05.013
    Abstract206)      PDF (664KB)(507)       Save
    The development of hepatocellular carcinoma (HCC) is closely related to the formation of tumour blood vessels. VEGF-mediated angiogenesis is a major driver of the immune escape response in tumours. VEGF binds to vascular endothelial growth factor receptor2 (VEGFR2) on endothelial cells, promoting endothelial cell proliferation and migration, inducing vascular changes in HCC, and thus promote the growth of hepatocellular carcinoma cells. Anti-VEGF and its receptor-targeted molecular drugs are currently effective new treatments for HCC. Monoclonal antibodies against VEGF and small-molecule tyrosine kinase inhibitors targeting VEGF have been shown to block its angiogenic activity, alleviate the inhibitory effect of the tumour microenvironment, and ultimately achieve tumour regression. This article provides a review of the research progress of VEGF/VEGFR inhibitors in HCC treatment.
    Related Articles | Metrics
    Research advance in progesterone therapy for endometrial cancer
    ZHANG Liyi, GUO Zifen
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (2): 230-235.   DOI: 10.12092/j.issn.1009-2501.2024.02.013
    Abstract257)      PDF (631KB)(498)       Save
    Endometrial cancer originates from the endometrium and is one of the common gynecologic malignancies, with its incidence and mortality rate increasing year by year. Although endometrial cancer is more prevalent in the peri- and post-menopausal female population, it has been an evident trend in recent years towards younger patients. For young patients who have not yet given birth but intend to do so, the application of progestins in endometrial cancer treatment has made significant progress in clinical practice. Considering the existence of large individual differences and unclear mechanisms of action in the clinical application of progestins, this paper aims to provide an overview of the current clinical application status, efficacy, hormone resistance, and its mechanisms in the context of hormone therapy.
    Related Articles | Metrics
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (4): 477-.  
    Abstract105)      PDF (263KB)(498)       Save
    Related Articles | Metrics
    Advances in targeted therapy for HER2-positive breast cancer
    LUO Shiping, ZHANG Jie, YU Yushuai, SONG Chuangui
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (8): 876-886.   DOI: 10.12092/j.issn.1009-2501.2023.08.004
    Abstract708)      PDF (761KB)(492)       Save
    Since the beginning of the 21st century, with the continuous development of anti-HER2-targeted drugs, more treatment options have been provided for patients with HER2-positive breast cancer and the survival prognosis has been significantly improved. At present, anti-HER2 targeted drugs mainly include monoclonal antibody drugs such as trastuzumab and pertuzumab, small molecule tyrosine kinase inhibitors such as lapatinib and neratinib, and antibody-drug conjugates such as T-DM1 and T-DXd, which play an extremely important role in different disease processes. The treatment of HER2-positive breast cancer is based on targeted therapy with trastuzumab. Early-stage patients with high risk factors can be treated with intensive targeted therapy to further improve the prognosis, while advanced patients need a reasonable arrangement of targeted therapy to overcome drug resistance and prolong survival. This article will review the current status, the latest research progress and the future prospects of anti-HER2 targeted therapy in different stages of the disease.
    Related Articles | Metrics
    Application of single-cell multi-omics sequencing technology in the study of ischemic stroke
    MENG Qian, WANG Yiwen, CUI Na, BAI Min, YANG Le, DING Yi
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (6): 690-699.   DOI: 10.12092/j.issn.1009-2501.2024.06.011
    Abstract216)      PDF (810KB)(492)       Save
    Ischemic stroke is an acute cerebrovascular disease with high disability and mortality, is the most common cause of death in China. Despite years of research, there are still no biomarkers for stroke, and the molecular mechanisms remain largely unknown. In the past decade, single-cell sequencing technology, as a rapidly developing emerging technology, can conduct high-throughput sequencing of multiple omics including genome, transcriptome, epigenome and proteome at the level of a single cell, providing a new way to discover biomarkers and analyze pathological mechanisms. In this paper, the progress of single-cell multi-omics sequencing technology and its application in the discovery of biomarkers, pathological mechanisms and drug development of ischemic stroke are introduced in detail, in order to provide valuable reference for precision medicine of ischemic stroke.
    Related Articles | Metrics
    Pharmacological  and clinical evaluation of Dorzagliatin in the treatment of type 2 diabetes
    DU Xiaoyu, LI Yumeng, WU Huizhen, QIU Bo
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (10): 1177-1183.   DOI: 10.12092/j.issn.1009-2501.2023.10.012
    Abstract319)      PDF (639KB)(486)       Save
    Dorzagliatin is a new dual action allosteric systemic glucokinase agonist (GKA), which can simultaneously activate the glucokinase (GK) in the pancreas and liver, promote insulin secretion and liver glycogen conversion in patients with type 2 diabetes, and improve pancreatic islets β-Cell function and insulin resistance simultaneously stimulate intestinal GK to regulate the secretion of Glucagon-like peptide-1 to play multiple hypoglycemic effects. As the first marketed GKA drug, it provides a new therapeutic approach for patients with type 2 diabetes. This article reviews the mechanism of action, pharmacokinetics, Drug interaction, clinical research and safety of Dorzagliatin.
    Related Articles | Metrics
    Advances in venlafaxine-related PK-PD relationship and influencing factors
    WANG Xin, WU Guodong, AN Ming, LI Gang, LIU Yang
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (7): 788-795.   DOI: 10.12092/j.issn.1009-2501.2023.07.010
    Abstract239)      PDF (879KB)(483)       Save
    Venlafaxine (VEN) is a new antidepressant drug that can effectively antagonize the reuptake of serotonin (5-HT) and norepinephrine (NE), compared with other antidepressants, venlafaxine pharmacokinetics/pharmacodynamics (PK-PD) is more regular and has the characteristics of less toxic side effects, fast oral absorption, and high bioavailability. This article reviews the PK-PD modelling of venlafaxine and its quantitative relationship, as well as the factors affecting the process in vivo of venlafaxine, including sex, body weight, individual genotype, liver and kidney function impairment, drug-drug interaction and other related factors.
    Related Articles | Metrics
    State of clinical application of meloxicam
    LI Xinyu, HUANG Xin
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (2): 189-197.   DOI: 10.12092/j.issn.1009-2501.2023.02.010
    Abstract456)      PDF (603KB)(476)       Save
    Meloxicam is a long-acting non-steroidal anti-inflammatory drug, which is mainly used in the treatment of chronic osteoarthritis and postoperative analgesia. Recent studies have found that the drug has great therapeutic potential in anti-tumor, improving cognitive impairment in Alzheimer's disease, mobilizing hematopoietic stem cells and so on. This paper reviewed the pharmacological mechanism of meloxicam, the adverse reactions in gastrointestinal tract, kidney, liver and cardiovascular aspects, summarized various forms of clinical application from the perspective of preparation, and summarized the current clinical treatment strategy of combining with Western medicine and Chinese medicine respectively.
    Related Articles | Metrics
    Research status of dialectical prevention and treatment of acute lung injury based on the theory of "Wei qi and Ying Xue"
    QI Xiaofeng, LUO Yali, XIAO Mengyong, ZHOU Shiqin, ZHOU Wen, AN Fangyu, WEI Benjun, LIU Yongqi
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (4): 429-437.   DOI: 10.12092/j.issn.1009-2501.2023.04.010
    Abstract194)      PDF (1983KB)(462)       Save
    Acute lung injury (ALI) is a common clinical critical respiratory disease. At present, the mechanism of the disease has not been fully elucidated, there is a lack of specific drugs in clinical practice and the mortality rate is high, which is a difficult problem in the medical field. In recent years, traditional Chinese medicine has exerted its unique advantages and efficacy in the prevention and treatment of ALI, which has aroused the attention of domestic and foreign scholars. Based on the theory of "Wei Qi Ying Xue", this paper discusses the current research status of prevention and treatment of ALI by traditional Chinese medicine, and analyzes its pathogenesis, clinical manifestations and corresponding analysis with TCM syndrome. According to the angle of "Wei Qi Ying Xue", the progress of syndrome differentiation and treatment is highly consistent with immune response, inflammatory response, oxidative stress and apoptosis, in order to find new ideas and medication for the prevention and treatment of ALI with integrated traditional Chinese and Western medicine.
    Related Articles | Metrics
    Research progress on signaling pathway of tanshinoneIIA in treatment of nerve injury after ischemic stroke
    QIN Wenxiu, XU Junfeng, YANG Ting, WANG Pingfei
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (6): 705-713.   DOI: 10.12092/j.issn.1009-2501.2023.06.014
    Abstract303)      PDF (758KB)(459)       Save
    Tanshinone IIA is one of the main active components of traditional Chinese medicine Salvia miltiorrhiza, which plays a pharmacological role, and has been proved by modern research to have the effect of anti ischemic stroke nerve damage. This article reviews the signal pathway and mechanism of tanshinone IIA on nerve damage after ischemic stroke in recent years through literature search, and finds that tanshinone IIA can regulate the activity and release of PI3K/Akt/mTOR, Nrf2, NF-κB. NLRP3, MAPK and other signal pathways, inhibit IL-6, IL-8 and TNF-α, up regulate the expression of neuron specific structural proteins, inhibit the activation and proliferation of astrocytes, play the role of anti neuroinflammation, oxidative stress, neuronal apoptosis, etc., thus reducing the damage of neurons after ischemic stroke, showing the mechanism characteristics of multi target, multi-channel and multi-level interaction. Based on this, this article briefly reviewed the neuroprotective mechanism of tanshinone IIA intervention on the above signal pathways after ischemic stroke, in order to provide reference for the clinical application and drug development of tanshinone IIA.
    Related Articles | Metrics
    The attenuating and potentiating effects of traditional Chinese medicine in immune checkpoint therapy
    ZHANG Zhipeng, CHEN Ziqi, TIAN Jianhui
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (3): 339-347.   DOI: 10.12092/j.issn.1009-2501.2024.03.013
    Abstract231)      PDF (649KB)(453)       Save
    Immunotherapy has become a global focus in cancer clinical practice and scientific research.In the past two years, PD-1\PD-L1 and CTLA-4 inhibitors, especially Nivolumab, Pembrolizumab, Atezolizumab and Lpilimumab, have been used in non-small cell lung cancer, colon cancer. Promising results have been obtained in malignancies such as melanoma and urinary tract cancer. Traditional Chinese medicine has a long history in China. Modulating immune checkpoints has certain advantages in treating malignant tumors, and it has shown good efficacy in improving its adverse events. This article reviews the role of traditional Chinese medicine in regulating immune checkpoints and improving adverse reactions and its application prospects in immunomodulatory treatment.
    Related Articles | Metrics
    Progress in perioperative application of tranexamic acid
    WANG Wenli, YAO Yiting, YANG Chun
    Chinese Journal of Clinical Pharmacology and Therapeutics    2024, 29 (2): 198-206.   DOI: 10.12092/j.issn.1009-2501.2024.02.010
    Abstract266)      PDF (649KB)(427)       Save
    Perioperative bleeding is closely related to the prognosis of patients, and massive blood loss can lead to serious adverse events. Tranexamic acid, a lysine derivative, exerts anti-fibrinolytic effects by competitively blocking lysine binding sites on plasminogen to achieve hemostasis. Perioperative use of tranexamic acid can effectively reduce the risk of bleeding and the need for blood transfusion, and reduce the risk of bleeding related complications and death. At present, the use of tranexamic acid for perioperative hemostasis is increasingly widespread, and it is gradually entering the consensus and guidelines in more surgical fields. In this paper, the mechanism of action, perioperative application and adverse reactions of tranexamic acid were reviewed, and the effectiveness and safety of tranexamic acid in different surgical types were discussed, so as to provide reference for the application and research of tranexamic acid in China.
    Related Articles | Metrics
    Research progress of biomarkers related to the efficacy of HER2 positive breast cancer
    XIANG Yimei, ZHANG Ningning, HUANG Yuxin, ZENG Xiaohua
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (8): 887-897.   DOI: 10.12092/j.issn.1009-2501.2023.08.005
    Abstract260)      PDF (702KB)(426)       Save
    Breast cancer is the most commonly diagnosed cancer and the main cause of cancer deaths among women worldwide. HER2 positive breast cancer accounts for 15% of all breast cancer. This subtype of breast cancer is highly invasive and has a very poor prognosis. With the development of anti-HER2 targeted therapy, the prognosis of these patients has been improved. However, some patients have poor response to the anti-HER2 therapy. Therefore, it is necessary to select biomarkers that can predict the therapeutic effect for improving the efficacy of these patients. This article describes the research progress of HER2 positive biomarkers for breast cancer, focusing on biomarkers related to the efficacy of targeted therapy, in order to provide some reference for future clinical optimization of targeted therapy.
    Related Articles | Metrics
    Study on PLGA-based nanoparticles in gynecological diseases
    CHEN Yetao, HE Junyu, WU Mengyao, WAN Fangzhu, HE Haibo, TANG Hongbo
    Chinese Journal of Clinical Pharmacology and Therapeutics    2023, 28 (4): 455-462.   DOI: 10.12092/j.issn.1009-2501.2023.04.013
    Abstract191)      PDF (958KB)(421)       Save
    Polylactic-co-glycolic acid (PLGA) has the characteristics of biocompatibility, biodegradability, modifiability, and slow release, which has attracted extensive attention in the treatment of gynecological diseases. This paper summarizes the relevant literature reports at home and abroad in recent years, expounds the research situation of PLGA nanoparticles as drug carriers in gynecological diseases such as ovarian cancer, breast cancer, cervical cancer and endometriosis, and looks forward to its great potential in clinical application in gynecological diseases, providing guidance for its prevention and treatment in gynecological diseases. 
    Related Articles | Metrics